News
Filter By:
- All
- Blog
- In the News
- Press Releases
- Publications
- All
- Blog
- In the News
- Press Releases
- Publications
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases
– New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets – Dyno to receive US$50 ...
Read More →
Dyno Therapeutics Unveils Path to Exponentially Reducing the Cost of In Vivo Gene Delivery at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
– Harnessing the convergence of exponential advances in AI, genome sequencing and DNA synthesis technologies, Dyno’s approach to enabling safe and highly efficient in vivo ...
Read More →
Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI
– The work will help advance design capabilities for gene therapies and other sequence-based medicines with potential for transformative patient impact – The collaboration will ...
Read More →
Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Meeting and SynBioBeta Global Synthetic Biology Conference
WATERTOWN, Mass., April 23, 2024 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential ...
Read More →
Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies
– 80x improvement vs. AAV2 in delivery to the retina seen in non-human primate (NHP) – – Head-to-head against other retina-IVT capsids, Dyno eCap 1 ...
Read More →
Dyno Therapeutics to Present on Breakthrough Optimized AAV Capsids for Eye and CNS Gene Delivery at ESGCT Annual Congress
WATERTOWN, Mass., October 11, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that expand the potential ...
Read More →
Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence
– Dyno bCap 1 exhibits 100x improvement versus AAV9 in delivery to the central nervous system (CNS) and 10x detargeting of liver after intravenous (IV) ...
Read More →
Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
WATERTOWN, Mass., May 2, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that can expand the ...
Read More →
Dyno is scaling gene therapy research with cloud-native tools like Argo Workflows and Hera
Cloud native tools such as Kubernetes and Argo Workflows are improving productivity, accelerating innovation, and increasing operational efficiency. These tools reduce the burden of infrastructure ...
Read More →
Leadership Updates
BOSTON, MA — April 25, 2023— We are pleased to announce the promotion of Adam Poulin-Kerstien, JD, PhD to General Counsel & appointment of Adrian Veres, ...
Read More →
Dyno Therapeutics Named on the Forbes List of America’s Best Startup Employers 2022
BOSTON, MA — March 11, 2022— Dyno Therapeutics is pleased to announce it has been recognized on the Forbes list of America’s Best Startup Employers 2022. ...
Read More →
Hera – the missing Argo Workflows Python SDK
At Dyno, we believe in collective innovation on our journey of empowering a diverse team of the best problem solvers to drive cutting edge science ...
Read More →
Dyno Therapeutics at Goldman Sachs Byte-ology Conference
Discussing the Convergence of Biotechnology and Technology Boston, Dec. 9, 2021 – Dyno Therapeutics announced today that management is scheduled to participate at the Goldman ...
Read More →
Dyno Therapeutics Named Emerging Company of the Year at New England Venture Capital Association’s 2021 NEVY Awards
BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life ...
Read More →
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 – Astellas Pharma Inc. (TSE: ...
Read More →
